CLINICAL TRIALS PROFILE FOR TECOVIRIMAT
✉ Email this page to a colleague
All Clinical Trials for Tecovirimat
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00431951 ↗ | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 | 2007-02-01 | The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers. |
NCT00431951 ↗ | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Completed | SIGA Technologies | Phase 1 | 2007-02-01 | The purpose of this study was to assess the safety, tolerability, and pharmacokinetics of a single, daily, oral dose of ST-246 (either 250, 400 or 800mg) administered for 21 days to 30 healthy, fed volunteers. |
NCT00728689 ↗ | Phase I Trial of an Investigational Small Pox Medication | Completed | National Institutes of Health (NIH) | Phase 1 | 2008-08-01 | The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers. |
NCT00728689 ↗ | Phase I Trial of an Investigational Small Pox Medication | Completed | SIGA Technologies | Phase 1 | 2008-08-01 | The purpose of this study was to evaluate the pharmacokinetic parameters and safety of a single dose of ST-246 400mg Form I versus ST-246 400mg Form V capsules in fed normal healthy volunteers. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tecovirimat
Condition Name
Clinical Trial Locations for Tecovirimat
Trials by Country
Clinical Trial Progress for Tecovirimat
Clinical Trial Phase
Clinical Trial Sponsors for Tecovirimat
Sponsor Name